903 related articles for article (PubMed ID: 26692181)
21. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
Nelson DB; McIntire DD; Leveno KJ
Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
[TBL] [Abstract][Full Text] [Related]
22. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
O'Brien JM; Lewis DF
Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
[TBL] [Abstract][Full Text] [Related]
23. Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.
Mainiero AD; Rouse DJ; Lopes V; Hughes BL
Obstet Gynecol; 2015 Jul; 126(1):103-8. PubMed ID: 26241262
[TBL] [Abstract][Full Text] [Related]
24. A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.
Awwad J; Usta IM; Ghazeeri G; Yacoub N; Succar J; Hayek S; Saasouh W; Nassar AH
BJOG; 2015 Jan; 122(1):71-9. PubMed ID: 25163819
[TBL] [Abstract][Full Text] [Related]
25. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
Coleman S; Wallace L; Alexander J; Istwan N
J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
[TBL] [Abstract][Full Text] [Related]
26. 17-α hydroxyprogesterone caproate for the prevention of preterm birth.
Gupta S; Roman AS
Womens Health (Lond); 2012 Jan; 8(1):21-30. PubMed ID: 22171770
[TBL] [Abstract][Full Text] [Related]
27. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P; Stahl B; Klinger G
Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
[TBL] [Abstract][Full Text] [Related]
28. 17-hydroxyprogesterone caproate for preterm rupture of the membranes: a multicenter, randomized, double-blind, placebo-controlled trial.
Combs CA; Garite TJ; Maurel K; Abril D; Das A; Clewell W; Heyborne K; How H; Huang W; Lewis D; Lu G; Miller H; Nageotte M; Porreco R; Sheikh A; Tran L;
Am J Obstet Gynecol; 2015 Sep; 213(3):364.e1-12. PubMed ID: 25979614
[TBL] [Abstract][Full Text] [Related]
29. Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.
Caritis SN; Costantine MM; Clark S; Stika CS; Kiley JW; Metz TD; Chauhan SP; Venkataramanan R;
Am J Obstet Gynecol MFM; 2023 Jul; 5(7):100980. PubMed ID: 37100349
[TBL] [Abstract][Full Text] [Related]
30. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.
Manuck TA; Watkins WS; Moore B; Esplin MS; Varner MW; Jackson GM; Yandell M; Jorde L
Am J Obstet Gynecol; 2014 Apr; 210(4):321.e1-321.e21. PubMed ID: 24594138
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
Eke AC; Sheffield J; Graham EM
Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
[TBL] [Abstract][Full Text] [Related]
33. Does 17-alpha hydroxyprogesterone caproate prevent recurrent preterm birth in obese women?
Heyborne KD; Allshouse AA; Carey JC
Am J Obstet Gynecol; 2015 Dec; 213(6):844.e1-6. PubMed ID: 26275354
[TBL] [Abstract][Full Text] [Related]
34. The effect of omega-3 supplementation on pregnancy outcomes by smoking status.
Kuper SG; Abramovici AR; Jauk VC; Harper LM; Biggio JR; Tita AT
Am J Obstet Gynecol; 2017 Oct; 217(4):476.e1-476.e6. PubMed ID: 28549983
[TBL] [Abstract][Full Text] [Related]
35. Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Caritis SN; Venkataramanan R; Thom E; Harper M; Klebanoff MA; Sorokin Y; Thorp JM; Varner MW; Wapner RJ; Iams JD; Carpenter MW; Grobman WA; Mercer BM; Sciscione A; Rouse DJ; Ramin S;
Am J Obstet Gynecol; 2014 Feb; 210(2):128.e1-6. PubMed ID: 24113254
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
[TBL] [Abstract][Full Text] [Related]
37. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
38. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic Regulation of the Nitric Oxide Pathway, 17-α Hydroxyprogesterone Caproate, and Recurrent Preterm Birth.
Manuck TA; Smeester L; Martin EM; Tomlinson MS; Smith C; Varner MW; Fry RC
Am J Perinatol; 2018 Jul; 35(8):721-728. PubMed ID: 29241278
[TBL] [Abstract][Full Text] [Related]
40. 17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.
Lim AC; Schuit E; Bloemenkamp K; Bernardus RE; Duvekot JJ; Erwich JJHM; van Eyck J; Groenwold RHH; Hasaart THM; Hummel P; Kars MM; Kwee A; van Oirschot CM; van Pampus MG; Papatsonis D; Porath MM; Spaanderman ME; Willekes C; Wilpshaar J; Mol BWJ; Bruinse HW
Obstet Gynecol; 2011 Sep; 118(3):513-520. PubMed ID: 21860279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]